Stanford Diffuse Intrinsic Pontine Glioma Research
Thank you for your interest in our recent publication in Nature Medicine. We hope the following announcement will provide you with additional information.
Patients with Diffuse Intrinsic Pontine Glioma, Thalamic Glioma or Spinal Cord Glioma
Thank you again for your interest in our research. We believe the use of GD2 CAR-T cells to treat diffuse midline gliomas such as DIPG holds great promise and we are actively working to move this type of therapy into use in humans.
GD2 CAR-T cells are currently being tested in clinical trials for children with neuroblastoma, but not all GD2 CAR-T cells are the same. Safety considerations are disease specific. As a result, GD2 CAR-T cell therapy in children with diffuse midline gliomas must be carefully studied, with as many safeguards as possible, to minimize risks to patients.
Please note: We do not yet have a clinical trial available for the use of GD2 CAR-T cells to treat diffuse midline gliomas, but we anticipate having a clinical trial available in the Spring of 2020. When a trial does become available, it will only be open to a small number of patients who meet strict inclusion criteria. Early clinical trials enroll a limited number of patients in order to test safety and determine side effects in humans. To learn more about clinical trials kindly review our FAQs.
Clinical trials for DIPG and other pediatric cancers
If you would like to explore currently available clinical trials at Stanford for which your child might be eligible, please click here or use the search box found in the upper right hand column of this page . If you want to cast a wider net, ClincialTrials.gov lists many of the clinical trials that are ongoing in the United States and is searchable by location and condition. The International DIPG Registry lists clinical trials that are specific to DIPG.
We understand the desire to have your child’s case reviewed by our experts. Though our staff is not able to comment or provide second opinions on cases via email or phone, we invite you, if you wish, to be seen in person for a second opinion. To make such an appointment, please call the Bass Center for Childhood Cancer and Blood Diseases at (650) 497-8953.
It can be challenging for patients outside of the U.S. to travel to Stanford for treatment or for participation in a clinical trial due to travel logistics and out of pocket costs. If you would still like to consider traveling to Stanford for patient care, please contact Stanford International Medical Services.